Brenzavvy Tablet
NDC Package 82381-2174-2
Package Information
Brenzavvy (bexagliflozin) tablets is bRENZAVVY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Limitations of Use BRENZAVVY is not recommended in patients with type 1 diabetes mellitus. This formulation utilizes a tablet delivery system. Marketed by Theracosbio, Llc, this product is identified by NDC 82381-2174 and is authorized under FDA application NDA214373.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 82381 - Theracosbio, Llc
- 82381-2174 - Brenzavvy
- 82381-2174-2 - 90 TABLET in 1 BOTTLE
- 82381-2174 - Brenzavvy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (82381-2174). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 82381-2174-2 identifies a specific commercial package of 90 tablet in 1 bottle of Brenzavvy, a human prescription drug labeled by Theracosbio, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 90 billable units per package. This tablet is formulated for oral use and contains bexagliflozin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Theracosbio, Llc on July 13, 2023. The current certification is valid through December 31, 2027.
How is this Theracosbio, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 82381217402. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.